Connect with us

Press Releases

Visus Therapeutics Appoints World-Renowned Ophthalmologist, Eric D. Donnenfeld, M.D., to Board of Directors

Dr. Donnenfeld brings significant clinical leadership and innovation experience to expand company’s board of directors.




(PRESS RELEASE) SEATTLE, WA — Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye, announced the appointment of Eric D. Donnenfeld, M.D., to the Company’s Board of Directors. Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert and pioneer in refractive, cornea and cataract surgery and is one of the leading refractive and cataract surgeons in the United States.

“I am thrilled to welcome Eric to the Visus Board,” said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics. “Eric brings tremendous leadership experience, not only as a world-renowned anterior segment specialist, but also in business management and innovation. He is the founding partner in OCLI Vision, one of the leading ophthalmology and optometry practices in the United States, and he has been involved in numerous clinical stage companies. We look forward to Eric’s many contributions as Visus advances and expands on its pipeline of innovative ophthalmic products.”

“Over the last two decades, I have had the honor of working closely with Eric on some of the most successful and challenging development programs in eyecare,” said Rhett Schiffman, M.D., M.S., M.H.S.A., co-founder, chief medical officer and head of research and development at Visus Therapeutics. “He is the premier clinician scientist and has played a key role in the clinical development of many of the most important therapies for the front of the eye. As Visus looks to change the way the leading causes of visual disability are treated, we look forward to Eric’s guidance.”

“I am very much looking forward to working closely with Ben and Rhett, the Board and leadership team, as Visus pioneers many exciting new investigational drug candidates, including what may be a best-in-class topical treatment of presbyopia—BRIMOCHOL PF,” said Dr. Donnenfeld. “Beyond that, Visus’ recently announced lens modulation program offers the real possibility of a non-surgical therapy that has the potential to treat cataracts and presbyopia, improving the quality of life of millions of people around the world. I am really excited to help Visus bring these and other potentially transformative treatments to our patients.”


Turn Patients Into Loyal Eyewear Shoppers

80% of patients are browsing eyewear online, are you influencing patients online before your competition? Join thousands of practices thriving with Optify, voted the #1 optical sales tool by EyeVote. Empower your opticians to save time, increase optical revenue, and maximize your EHR data and website with a seamless optical plug-in that keeps patients buying from YOU! Now through August 31st receive a $25 UberEats® gift card when you complete a 15 min demo. Book your demo here..

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular